Niagen Bioscience rides rising interest in science-backed healthy aging, but cheaper copycat products and shifting rules could make it harder to keep prices and profits steady. The upside may come from new clinic and at-home channels and upcoming medical study results, but delays or weak data could change the story.Read more
A little-known supplement maker tries to turn its “healthy aging” ingredient into a bigger business by pushing into clinics, at-home treatments, and telehealth. The real upside may come from early medical research that could attract drug partners—but competition, regulation, and trial results could quickly change the story.Read more
ChromaDex is pushing its Niagen ingredient into clinic-based IVs and injections while its online sales channel keeps picking up speed, which could change how fast the business grows. But heavy competition, supply hiccups, and regulatory and legal outcomes could decide whether this expansion turns into lasting profits or stalls out.Read more
No trending discussion available.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
